Hep C Treatment for Genotype 1

FDA approves New Hep C Treatment Zepatier by Merck for Genotypes 1 and 4

FacebookTwitterLinkedInEmailPrint

Jan 28, 2016 the U.S. FDA approved the newest treatment for chronic Hepatitis C, Zepatier, a fixed-dose combination (elbasvir and grazoprevir) which can be used with or without ribavirin.  Zepatier produced by Merck provides another oral treatment option without interferon for patients with genotype 1 and 4. Cure Rate In six clinical trial studies, Zepatier …

Zepatier
Continue Reading »